ad image
PPD® Laboratories Named a Top Innovator in Drug Development

PPD® Laboratories Named a Top Innovator in Drug Development

Jan 08, 2018PR-M01-18-NI-016

Preclarus® investigator site portal and mobile app recognized by CenterWatch

WILMINGTON, N.C. (January 5, 2018)  Pharmaceutical Product Development, LLC (PPD) today announced that PPD® Laboratories has been recognized as a 2018 top innovator in drug development by CenterWatch, a leading publisher of clinical trials information for clinical research professionals.

PPD’s Preclarus® investigator site portal and companion mobile application were acknowledged for industry leadership in the CenterWatch Monthly 25th anniversary special edition, which spotlights top innovators in clinical research.

A fully integrated component of PPD — a leading global contract research organization — PPD Laboratories offers the most comprehensive set of laboratory services in the industry, spanning bioanalytical, biomarkers, central lab, GMP and vaccine sciences.

“At PPD, innovation is embedded within everything we do because we believe it is essential to our ongoing ability to support our clients’ success,” said Christopher Fikry, M.D., executive vice president of PPD Laboratories. “As is evident with the Preclarus investigator site portal, we are focused on fostering an environment that promotes and uses innovation to provide efficiencies, advancements and differentiation that help our customers deliver life-changing therapies.”

The Preclarus investigator site portal is a web-based platform, accessible via standard web browsers, that streamlines site activities associated with clinical trials, such as subject registration, sample accessioning, test result reporting and critical value alerts.

The portal uses barcode scanning technology to register a sample immediately after an investigator site receives it from a patient. This process inserts the sample’s information directly into PPD Laboratories’ global database in real time, alerting the lab, clients and other stakeholders.

The portal’s real-time feedback has resulted in a 67 percent reduction in the number of exceptions and queries sites traditionally experience that can adversely impact the length of the drug development process.

In 2018, to further support the schedules and workflows of research professionals at investigator sites, PPD Laboratories will extend the functionality of the online Preclarus investigator site portal to a mobile application to help manage clinical trial data. Just as with the web platform, principal investigators, clinical trial managers and other clinical site staff will have the ability to view alerts, manage supplies and perform accessioning activities wherever they are by simply using mobile devices, such as smartphones or tablets.



PPD Contacts

Media:
Randy Buckwalter
Tel: +1 919 456 4425
Email: randy.buckwalter@ppdi.com 

Investors:
Nate Speicher
Tel: +1 910 558 6783
Eamil: nate.speicher@ppdi.com